Overview
SCNX market data
Price History
SCNX price chart · 1M
- O
- 0.378500
- H
- 0.387600
- L
- 0.378500
- C
- 0.387600
- Vol
- 1,773.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.38
- Previous Close
- $0.39
- Day High
- $0.39
- Day Low
- $0.38
- 52 Week High
- $0.48
- 52 Week Low
- $0.30
- 7 Day Return
- -17.85%
- 30 Day Return
- +4.39%
- 90 Day Return
- -6.47%
- 1 Year Return
- +2.00%
- Daily Notional Volume
- $687.2 Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.70 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.09 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 12.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,084.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.24 – $2.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $18.2M · P/B 0.30 · P/S 28.19.
Company News
8-K filing — Scienture Holdings, Inc. (SCNX)SEC EDGAR · Aug 20, 2026, 8:05 PM
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M EstimateBenzinga · Aug 14, 2026, 12:23 PM
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in USBenzinga · Aug 12, 2026, 11:46 AM
EXCLUSIVE: Scienture Commences Commercial Launch and Fulfillment of Initial Rezenopy Orders; Targets Execution Through End of 2026 By Expanding Payer Coverage, Product Access, and Institutional AdoptionBenzinga · Aug 12, 2026, 11:45 AM
Scienture To Begin Shiptments Of REZENOPY Nasal Spray 10mg To U.S. Pharmaceutical Wholesalers Later This MonthBenzinga · Jul 9, 2026, 12:20 PM
Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel PartnershipsBenzinga · Jun 18, 2026, 12:15 PM
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid OverdoseBenzinga · Jun 16, 2026, 12:55 PM
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial LaunchBenzinga · Jun 9, 2026, 11:50 AM
EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-JulyBenzinga · Jun 9, 2026, 11:50 AM
Scienture Holdings Holds Exclusive U.S. Distribution Rights For Kindeva Drug Subsidiary Summit BioSciences' Rezenopy Nasal Spray, Which Received A U.S. Patent Effective May 12Benzinga · Jun 2, 2026, 12:23 PM